ABSORB scaffold dissolves in the body, wins Wall Street Journal Technology Innovation Award.
Innovation is alive and well at Abbott Laboratories, where global health company won a 2011 Wall Street Journal Technology Innovation Award for its http://www.abbott.com/news-media/press-releases/2011 oct17.htm ™ bioresorbable vascular-scaffold.
The company Abbott Park, IL-based stated that the award was in recognition of the fourth Technology Innovation Award for Abbott in five years. Release from release explained, "is an implantable device to absorb that restores blood flow by opening a blocked artery and support to the boat until the device dissolves. Once in place and absorb dissolved in about two years, leaving patients with a treated vessel free of a permanent metallic implant.
"The drug-eluting device first of its kind for coronary artery disease and absorb, is polylactide, a proven biocompatible material that is commonly used in medical implants such as dissolvable sutures. Because a permanent metallic implant is not left back glass can naturally restore functions, which is one of the features that make this device is an important innovation for patients in the evaluation and treatment of coronary artery disease. "
"Absorb represents the best in scientific innovation, as it has the potential to change the way physicians practice medicine and improve outcomes for their patients," said Robert B. Hance, senior vice president, Vascular, Abbott. "We are very pleased that this innovation has been developed in the U.S. for nearly a decade, has the potential to advance the treatment of patients around the world. Abbott is honored to receive this prestigious award."
In January, Abbott announced that absorb received CE Mark in Europe for the treatment of coronary artery disease. In the United States and absorb, currently under development and not available for sale. ABSORB is being evaluated in 40 clinical centers in 20 countries around the world.
Abbott spokesman Jonathan Hamilton Health absorbing packing are manufactured at company facilities in California in a clean room environment. He said three sizes have been granted the CE mark (2.5 x 18 mm, 3.0 x 18 and 3.0 x 28 mm).
Asked if ABSORBER would be considered a combination product, Hamilton said: "absorb this type of product is own -. A drug and device combination product resorbable device has enough unique attributes that deserves its own class."
What kind of material is the device that is placed in? "It is placed in the same type of packaging used with traditional drug-eluting stent - a coil, foil pouch, and a box," he said, noting that the company did not disclose the details of packaging supplier. The product is shipped and stored in a manner similar to traditional stents, he said.
As competing devices, Packaging Healthcare Hamilton said, "The design and performance of absorbing Abbott puts years ahead of any technology company seeks to develop a BVS and is an example of how the company is revolutionizing the way patients coronary artery disease are treated. Given the many technical challenges involved in creating a soluble polymer stent, Abbott is the only company of major stent manufacturers to achieve the full development of bioabsorbable drug eluting device to treat coronary artery disease. "
In the future, Hamilton said: "We are working with the FDA to define the necessary data and the timing of our U.S. clinical trial. Assuming all proceeds as planned, we intend to enroll the first patient in the overall process in the first half of 2012. We anticipate filing for approval absorb in the U.S. in 2015, we are not speculating on the date of commercial availability We are also working with regulatory authorities in Japan and other markets the device to absorb more patients "..